News
Minomic announces completion of demerger of GlyTherix Ltd
Demerger clears the path for therapeutic company capital raising Sydney, Australia, 25 September 2018: Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd, at a...
read more
Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China
Dr Brad Walsh awarded first prize to boost Minomic’s efforts for MiCheck® China launch - offering a better solution for prostate cancer diagnosis 13 September 2018: [Sydney] Diagnostic company Minomic International Ltd today announced it had secured first prize at the...
read more
Minomic secures key patent in the United States and China
Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer Sydney, Australia, 5 September 2018: Minomic International Ltd (Minomic), an immuno-oncology company specializing in the...
read more
Minomic completes Prospective Clinical Study using MiCheck® to assist in diagnosis of prostate cancer
58% Fewer patients proceed to Biopsy. US Rollout well advanced. May 17, 2018: [Sydney] Australian immuno-oncology company Minomic International Ltd is pleased to announce the completion of its prospective clinical trial of the company’s novel prostate cancer...
read more
ASCO meeting abstract: Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial
A poster with headline results of the MiCheck-01 prospective trial was presented by Dr Brad Walsh, Minomic’s CEO at ASCO GU Cancers Symposium 2018 on 8 February. The 350-patient study highlights the test’s performance in differentiating aggressive from non-aggressive...
read more
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic's head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary in vitro ADCC assay results revealed the...
read more
Minomic Launches US Prospective Study of MiCheck® Prostate Cancer Test
Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access July 18, 2017: [Sydney] Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US...
read more